Background/Aims: Inflammatory cytokines may enhance renal injury in post-diarrheal hemolytic uremic syndrome (Stx HUS) by enhancing the cytotoxic effect of Shiga toxins (Stx). The sources of inflammatory cytokines in Stx HUS are unclear. Since Stx-1 potently inhibits protein synthesis by glomerular epithelial cells (GEC) and increases cytokine release by renal epithelial cells, we examined Stx-1 regulation of cytokine production by human GEC. Methods: Stx-1 (and cycloheximide (CHX), another protein synthesis inhibitor) cytotoxicity, protein synthesis inhibition, and effect on interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor (TNF) release and mRNA levels were determined. Results: Stx-1 alone had a modest stimulatory effect on inflammatory cytokine production by GEC that occurred at toxin concentrations ranging from minimal to 50% inhibition of protein synthesis. CHX, at concentrations that produced similar inhibition of protein synthesis, increased IL-1, IL-6, and TNF protein release and mRNA accumulation, but in a different time- and dose-dependent pattern than Stx. Lipopolysaccharide (LPS) did not change IL-1, but stimulated IL-6 and TNF production. LPS and Stx-1 combined stimulated production of all three cytokines to a greater extent than either toxin alone. Conclusion: These data indicate that: (1) Stx-1 alone modestly stimulates GEC inflammatory cytokine production; (2) LPS and Stx-1 combined can potently enhance GEC cytokine release, and (3) this action of Stx-1 may relate in part to inhibition of protein synthesis but cannot be fully attributed to this effect.

Keywords:
Shiga toxin, Glomerular epithelial cells, Cytokine, Lipopolysaccharide
1.
Robson WLM, Leung AKC, Kaplan BS: Hemolytic-uremic syndrome. Curr Prob Pediatr 1993;23:16–33.
2.
Remuzzi G, Ruggenenti P, Bertani T: Thrombotic microangiopathy; in Tisher CC, Brenner BM (eds): Renal Pathology with Clinical and Functional Correlations, ed 2. Philadelphia, Lippincott, 1994, pp 1154–1184.
3.
Lingwood CA: Verotoxin-binding in human renal sections. Nephron 1994;66:21–28.
4.
Tesh VL, Ramegowda B, Samuel JE: Purified shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 1994;62:5085–5094.
5.
Hughes A, Stricklett P, Kohan D: Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. Kidney Int 1998;54:1093–1106.
6.
Hughes A, Stricklett P, Kohan D: Cytotoxic effect of shiga toxin-1 on human proximal tubule cells. Kidney Int 1998;54:426–437.
7.
Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG: Shiga toxin-associated hemolytic uremic syndrome: Interleukin-1β enhancement of shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993;61:3886–3891.
8.
van de Kar N, Monnens LAH, Karmali MA, van Hinsbergh VWM: Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992;80:2755–2764.
9.
Jacewicz MS, Mobassaleh M, Dinarello C, Wagner D, King A, Keusch GT: Characterization of cytokine induced modulation of shiga-like toxin 1 (SLT1) receptors on endothelial cells. 2nd International Symposium and Workshop on Verocytotoxin (Shiga-Like Toxin)-Producing Escherichia coli Infections, Bergamo, 1994, p 64.
10.
van Setten P, van Hinsbergh V, van der Velden T, van der Kar N, Vermeer M, Mahan J, Assmann K, van den Heuvel L, Monnens L: Effects of TNFα on verocytotoxin cytotoxicity in purified glomerular microvascular endothelial cells. Kidney Int 1997;51:1245–1256.
11.
Karpman D, Andreasson A, Thysell H, Kaplan B, Svanborg C: Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995;9:694–699.
12.
Lopez EL, Contrini MM, De Rosa MF, Devoto S, Grana MG, Genero MH, Canepa C, Cleary TG: Tumor necrosis factor levels in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. 2nd International Symposium and Workshop on Verocytotoxin (Shiga-Like Toxin)-Producing Escherichia coli infections, Bergamo, 1994, p 81.
13.
Lopez E, Contrini M, Devoto S, de Rosa M, Grana M, Genero M, Canepa C, Gomez H, Cleart T: Tumor necrosis factor concentrations in hemolytic uremic syndrome patients and children with bloody diarrhea in Argentina. Pediatr Infect Dis 1995;14:594–598.
14.
Karpman D, Andreasson A, Thysell H, Kaplan BS, Svanborg C: Serum and urinary cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. 2nd International Symposium and Workshop on Verocytotoxin (Shiga-Like Toxin)-Producing Escherichia coli Infections, Bergamo, 1994, p 45.
15.
Oosterwijk E, Kalisiak A, Wakka J, Scheinberg D, Old L: Monoclonal antibodies and galα1-4galβ1-4glc (Pk, CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors. J Cancer 1991;48:848–854.
16.
Williams J, Boyd B, Nutikka A, Lingwood C, Barnett Foster D, Milford D, Tayor C: A comparison of the effects of verocytotoxin-1 on primary human renal cell cultures. Toxicol Lett 1999;105:47–57.
17.
Hughes A, Stricklett P, Schmid D, Kohan D: Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. Kidney Int 2000;57:2350–2359.
18.
Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484–15488.
19.
Baud L, Oudinet J-P, Bens M, Noe L, Peraldi M-N, Rondeau E, Etienne J, Ardaillou R: Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 1989;35:1111–1118.
20.
Pirotzky E, Delattre RM, Hellegouarch A, Lonchampt MO, Aarden L, Braquet P, Galanaud P: Interleukin-6 production by tumor necrosis factor and lipopolysaccharide-stimulated rat renal cells. Clin Immunol Immunopathol 1990;56:271–279.
21.
Loppnow H, Libby P: Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 1989;122:493–503.
22.
Kita T, Tanaka N, Nagano T: The immunochemical localization of tumour necrosis factor and leukotriene in the rat kidney after treatment with lipopolysaccharide. Int J Exp Pathol 1993;74:471–479.
23.
Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.
24.
Hughes AK, Stricklett PK, Padilla E, Kohan DE: Regulation of endothelin-1 production by human mesangial cells: Effect of oxygen radicals. Kidney Int 1996;49:181–189.
25.
Mundel P, Reiser J, Kriz W: Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 1997;8:697–705.
26.
Moutabarrik A, Nakanishi I, Ishibashi M: Interleukin-6 and interleukin-6 receptor are expressed by cultured glomerular epithelial cells. Scand J Immunol 1994;40:181–186.
27.
Neale T, Ruger B, Macaulay H, Dunbar P, Hasan Q, Bourke A, Murray-McIntosh R, Kitching A: Tumor necrosis factor-α is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 1995;146:1444–1454.
28.
Suzuki D, Miyazaki M, Naka R, Koji T, Yagame M, Jinde K, Endoh M, Nomoto Y, Sakai H: In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995;44:1233–1238.
29.
Sariban E, Imamura K, Luebbers R, Kufe D: Transcriptional and posttranslational regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest 1988;81:1506–1510.
30.
Collart M, Baeuerle P, Vassalli P: Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four KB-like motifs and of constitutive and inducible forms of NF-KB. Mol Cell Biol 1990;10:1498–1506.
31.
Jarrus N, Kaempfer R: Induction of human interleukin-1 gene expression by retinoic acid and its regulation at processing of precursor transcripts. J Biol Chem 1994;269:23141–23149.
32.
Yamabe H, Yoshikawa S, Ohsawa H, Inuma H, Miyata M, Sasaki T, Kaisuka M, Tamura N, Onodera K: Tissue factor production by cultured rat glomerular epithelial cells. Nephrol Dial Transplant 1993;8:519–523.
33.
Prodjosudjadi W, Gerritsma J, Klar-Mohamad N, Gerritsen A, Bruijn J, Daha M, van Es L: Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 1995;48:1477–1486.
34.
Watanabe K, Kinoshita S, Nakagawa H: Gelatinase secretion by glomerular epithelial cells. Nephron 1990;56:405–409.
35.
Yanagisawa M, Imai H, Fukushima Y, Yasuda T, Miura A, Nakamoto Y: Effects of tumour necrosis factor alpha and interleukin 1 beta on the proliferation of cultured glomerular epithelial cells. Virchows Arch 1994;424:581–586.
36.
Marsden PA, Brenner BM: Transcriptional regulation of the endothelin-1 gene by TNF-α. Am J Physiol 1992;262:C854–C861.
37.
Radeke HH, Meier B, Topley N, Flöge J, Habermehl GG, Resch K: Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells. Kidney Int 1990;37:767–775.
38.
Hruby ZW, Cybulsky AV, Lowry RP: Effects of tumor necrosis factor on glomerular mesangial and epithelial cells in culture. Nephron 1990;56:410–413.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.